JP2023529691A5 - - Google Patents

Info

Publication number
JP2023529691A5
JP2023529691A5 JP2022575895A JP2022575895A JP2023529691A5 JP 2023529691 A5 JP2023529691 A5 JP 2023529691A5 JP 2022575895 A JP2022575895 A JP 2022575895A JP 2022575895 A JP2022575895 A JP 2022575895A JP 2023529691 A5 JP2023529691 A5 JP 2023529691A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
therapeutically effective
approximately
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022575895A
Other languages
English (en)
Japanese (ja)
Other versions
JP7857235B2 (ja
JP2023529691A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036620 external-priority patent/WO2021252630A1/en
Publication of JP2023529691A publication Critical patent/JP2023529691A/ja
Publication of JP2023529691A5 publication Critical patent/JP2023529691A5/ja
Application granted granted Critical
Publication of JP7857235B2 publication Critical patent/JP7857235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022575895A 2020-06-10 2021-06-09 慢性腎疾患を処置または防止するための方法 Active JP7857235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063037469P 2020-06-10 2020-06-10
US63/037,469 2020-06-10
US202163195411P 2021-06-01 2021-06-01
US63/195,411 2021-06-01
PCT/US2021/036620 WO2021252630A1 (en) 2020-06-10 2021-06-09 Methods for treating or preventing chronic kidney disease

Publications (3)

Publication Number Publication Date
JP2023529691A JP2023529691A (ja) 2023-07-11
JP2023529691A5 true JP2023529691A5 (cg-RX-API-DMAC10.html) 2024-06-10
JP7857235B2 JP7857235B2 (ja) 2026-05-12

Family

ID=78846498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575895A Active JP7857235B2 (ja) 2020-06-10 2021-06-09 慢性腎疾患を処置または防止するための方法

Country Status (10)

Country Link
US (1) US20230218563A1 (cg-RX-API-DMAC10.html)
EP (1) EP4164624A4 (cg-RX-API-DMAC10.html)
JP (1) JP7857235B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230024354A (cg-RX-API-DMAC10.html)
AU (1) AU2021288679A1 (cg-RX-API-DMAC10.html)
CA (1) CA3181902A1 (cg-RX-API-DMAC10.html)
IL (1) IL298833A (cg-RX-API-DMAC10.html)
MX (1) MX2022015678A (cg-RX-API-DMAC10.html)
TW (1) TW202214228A (cg-RX-API-DMAC10.html)
WO (1) WO2021252630A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2291189B1 (en) 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2014149789A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treament of hyperuricemia
AU2017298142B2 (en) * 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
WO2019195118A1 (en) * 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2020070539A1 (en) * 2018-10-01 2020-04-09 Astrazeneca Ab Compositions for reducing serum uric acid
JP2022511800A (ja) * 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CA3140412A1 (en) * 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia

Similar Documents

Publication Publication Date Title
EP2086519B1 (en) Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
JP2012502015A5 (cg-RX-API-DMAC10.html)
JP2006523216A5 (cg-RX-API-DMAC10.html)
WO2008101064A1 (en) Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
CN103429236A (zh) 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
KR20130097775A (ko) 테오필린과 페북소스타트의 병용 치료 방법
Rashid The efficacy and safety of PDE5 inhibitors
JP2022510303A5 (cg-RX-API-DMAC10.html)
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
JP2020523334A5 (cg-RX-API-DMAC10.html)
JP2022529208A5 (cg-RX-API-DMAC10.html)
KR20090037347A (ko) HMG-CoA 환원효소억제제와 담즙산을 포함하는 C형 간염 치료용 약학조성물
JP2020522560A5 (cg-RX-API-DMAC10.html)
JP2004519424A5 (ja) インシュリン分泌促進剤およびHMG−Co−Aレダクターゼ阻害剤およびACE阻害剤から選択される活性成分を含む組み合わせ
Hiramoto et al. Evidence-based analysis: postoperative gastric bleeding: etiology and prevention
CN105434417A (zh) 丹酚酸a在制备抗血管内膜增厚、抗血管成形术后和/或支架内再狭窄药物中的应用
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
KR20250088666A (ko) 손 습진의 치료
JPWO2022071578A5 (cg-RX-API-DMAC10.html)
IL300406A (en) Preparations and methods for the treatment or prevention of disease associated with beta corona virus infection
CN101229372A (zh) 一种治疗高血压的药物组合物
Rubio et al. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil
Caiati et al. Cardiorenal syndrome triggered by slowly progressive drugs toxicity-induced renal failure along with minimal mitral disease: A case report
Tissières et al. Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension
S. Hiremath et al. Recent patents on oral combination drug delivery and formulations